拉米夫定联合苦参素治疗慢性乙型肝炎的疗效观察

目的：探讨拉米夫定联合苦参素治疗慢性乙型肝炎的临床疗效。方法：将146例慢性乙型肝炎患者随机分成治疗组（拉米夫定联合苦参素治疗）和对照组（单用拉米夫定治疗）各73例，用ELISA法检测HBeAg、抗-HBs、HBeAg、抗-Hbe、抗-HBc，用PCR法检测HBV DNA，观察两组的临床疗效和HBeAg、HBV DNA阴转率。同时观察肝功能及相应临床症状和体征变化。结果：治疗组总有效率为93．15％，显著高于对照组的75．34％（P〈0．05）；治疗组HBeAg阴转率、HBsAg阴转率、HBeAg／HBeAb转换率和HBV DNA阴转率分别为71．23％、26．86％、54．79％和86．30％，显著高于对照组的50．68％、10．15％、35.62％、61．64％（P均〈0．05）。治疗组的肝功能及相应临床症状和体征改善均优于对照组（P均〈0．05）。结论：拉米夫定联合苦参素治疗慢性乙型肝炎，是一种安全有效的治疗方法，值得临床推广应用。

OBSERVATION OF THE EFFECT ON TREATMENT OF CHRONIC HEPATITIS B BY LAMIVUDINE COMBINATION WITH OXYMATRINE

Objective:To study the therapeutical effect of lamivudine combined with oxymatrine for treatment of chronic hepatitis B.Methods:146 patients were divided randomly into therapy group(73 patients, lamivudine combined with oxymatrine therapy) and control group(73 patients, lamivudine therapy only).HBeAg,anti-HBs,HBeAg,anti-Hbe and anti-HBc were detected by ELISA and HBV DNA was detected by PCR.The HBeAg and HBV DNA negativie rates,liver function,the symptoms and signs of all patients were observed closely.Result:The total effective rates in therapy group and control group were 93.15% and 75.34% respectively. the difference between the two groups was significant(P<0.05). HBeAg and HBsAg negative transfer rates, the tranfer rate from HBeAg to HBeAb and HBV DNA negative rate in therapy group were 71.23%,26.86%,54.79% and 86.30%,respectively.In the control group,they were 50.68%,10.15%,35.62% and 61.64%,and the difference of the result was significant(P<0.05). The effects on liver function and symptoms in therapy group were significantly improved compared with those in the control group(P<0.05).Conclusion:Lamivudine combined with oxymatrine is effective and safe in treatment of chronic hepatits B and worth clinical application.